WO2007101158A3 - Methods and compositions for the treatment of gastrointestinal disorders - Google Patents
Methods and compositions for the treatment of gastrointestinal disorders Download PDFInfo
- Publication number
- WO2007101158A3 WO2007101158A3 PCT/US2007/062815 US2007062815W WO2007101158A3 WO 2007101158 A3 WO2007101158 A3 WO 2007101158A3 US 2007062815 W US2007062815 W US 2007062815W WO 2007101158 A3 WO2007101158 A3 WO 2007101158A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- constipation
- compositions
- conditions
- dyspepsia
- Prior art date
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010010774 Constipation Diseases 0.000 abstract 4
- 201000006549 dyspepsia Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 abstract 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 abstract 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000005078 Colonic Pseudo-Obstruction Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 abstract 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 abstract 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 206010060865 duodenogastric reflux Diseases 0.000 abstract 1
- 208000001288 gastroparesis Diseases 0.000 abstract 1
- 208000024798 heartburn Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Abstract
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor and predicted metabolites of such peptides.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/280,374 US20090192083A1 (en) | 2006-02-24 | 2007-02-26 | Methods and compositions for the treatment of gastrointestinal disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77723906P | 2006-02-24 | 2006-02-24 | |
| US60/777,239 | 2006-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007101158A2 WO2007101158A2 (en) | 2007-09-07 |
| WO2007101158A3 true WO2007101158A3 (en) | 2008-05-02 |
Family
ID=38459777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/062815 WO2007101158A2 (en) | 2006-02-24 | 2007-02-26 | Methods and compositions for the treatment of gastrointestinal disorders |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20090192083A1 (en) |
| WO (1) | WO2007101158A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539132T3 (en) | 2001-03-29 | 2015-06-26 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| EP3255149A3 (en) * | 2006-05-02 | 2018-04-18 | Intrexon Actobiotics NV | Microbial intestinal delivery of obesity related peptides |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20110065741A1 (en) | 2009-02-26 | 2011-03-17 | Salix Pharmaceuticals, Ltd. | Methods for treating irritable bowel syndrome (ibs) |
| US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009256156B2 (en) | 2008-06-04 | 2014-09-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| AU2009322285B2 (en) * | 2008-12-03 | 2016-07-28 | Bausch Health Ireland Limited | Formulations of guanylate cyclase C agonists and methods of use |
| RU2012109415A (en) | 2009-08-13 | 2013-09-20 | Айронвуд Фармасьютикалз, Инк. | METHOD FOR MODULATION OF PHARMACODYNAMIC EFFECT OF ORAL-INJECTED GUANILATICYCLASE RECEPTOR AGONISTS |
| EP2505188A1 (en) * | 2009-12-02 | 2012-10-03 | Bettina Heil | Suppository for rectal, vaginal or urethral administration |
| US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
| AR080056A1 (en) | 2010-02-01 | 2012-03-07 | Novartis Ag | CICLOHEXIL-AMIDA DERIVATIVES AS ANTAGONISTS OF CRF RECEIVERS |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2810243C (en) | 2010-09-15 | 2021-04-20 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US8979797B2 (en) | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
| WO2012155114A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Peptides derived from uroguanylin and their use in gastrointestinal disorders |
| JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CN105979959B (en) | 2013-08-09 | 2021-11-30 | 阿德利克斯公司 | Compounds and methods for inhibiting phosphate transport |
| US20160367623A1 (en) * | 2015-06-16 | 2016-12-22 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050020811A1 (en) * | 2003-01-28 | 2005-01-27 | Currie Mark G. | Methods and compositions for the treatment of gastrointestinal disorders |
-
2007
- 2007-02-26 US US12/280,374 patent/US20090192083A1/en not_active Abandoned
- 2007-02-26 WO PCT/US2007/062815 patent/WO2007101158A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050020811A1 (en) * | 2003-01-28 | 2005-01-27 | Currie Mark G. | Methods and compositions for the treatment of gastrointestinal disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090192083A1 (en) | 2009-07-30 |
| WO2007101158A2 (en) | 2007-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007101158A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2006086653A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2007022531A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2005016244A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2004069165A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2008002971A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| SG153824A1 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2011103311A3 (en) | Treatments for gastrointestinal disorders | |
| MX2014001798A (en) | Treatments for gastrointestinal disorders. | |
| WO2005074575A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2007062168A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| WO2006102069A3 (en) | Methods and compositions for the treatment of hypertension and gastrointestinal disorders | |
| HK1082200A1 (en) | Compositions and methods for the therapy of inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12280374 Country of ref document: US |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07757491 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07757491 Country of ref document: EP Kind code of ref document: A2 |